These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28277401)

  • 21. [Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients].
    Klieser E; Lehmann E; Tegeler J
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():14-7. PubMed ID: 1683333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zotepine-induced convulsion at a low dose in a case of paranoid schizophrenia.
    Ali M; Das S
    Psychiatry Clin Neurosci; 2018 May; 72(5):374. PubMed ID: 29363876
    [No Abstract]   [Full Text] [Related]  

  • 23. Improvement in QTc prolongation induced by zotepine following a switch to perospirone.
    Suzuki Y; Watanabe J; Sugai T; Fukui N; Ono S; Tsuneyama N; Saito M; Someya T
    Psychiatry Clin Neurosci; 2012 Apr; 66(3):244. PubMed ID: 22443250
    [No Abstract]   [Full Text] [Related]  

  • 24. [Hyperlipidemia--side-effect of the treatment with an atypical antipsychotic (zotepine)?].
    Wetterling T
    Psychiatr Prax; 2002 Nov; 29(8):438-40. PubMed ID: 12436365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin.
    Kondo T; Otani K; Ishida M; Tanaka O; Kaneko S; Fukushima Y
    Ther Drug Monit; 1994 Apr; 16(2):120-4. PubMed ID: 7912012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical effectiveness of zotepine in treatment of negative schizophrenic symptoms. Results of an open and a double-blind controlled trial].
    Müller-Spahn F; Dieterle D; Ackenheil M
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():30-5. PubMed ID: 1683337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zotepine: a clinical review.
    Green B
    Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):181-6. PubMed ID: 19199377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol.
    Hwang TJ; Lin SK; Lin HN
    J Formos Med Assoc; 2001 Dec; 100(12):811-6. PubMed ID: 11802520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study.
    Lin CC; Chiu HJ; Chen JY; Liou YJ; Wang YC; Chen TT; Bai YM
    J Clin Psychopharmacol; 2013 Apr; 33(2):211-4. PubMed ID: 23422395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A self-limiting case of atypical neuroleptic malignant syndrome associated with zotepine.
    Hsu WC; Lin ST; Chen CC; Tsang HY; Huang MF
    J Clin Psychopharmacol; 2011 Oct; 31(5):667-9. PubMed ID: 21881455
    [No Abstract]   [Full Text] [Related]  

  • 31. Three cases of alopecia areata induced by zotepine.
    Kubota T; Ishikura T; Jibiki I
    Acta Neurol (Napoli); 1993 Jun; 15(3):200-3. PubMed ID: 7901970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia.
    Cooper SJ; Tweed J; Raniwalla J; Butler A; Welch C
    Acta Psychiatr Scand; 2000 Mar; 101(3):218-25. PubMed ID: 10721870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Body weight increase: a side effect of zotepin (Nipolept)?].
    Wetterling T; Müssigbrodt H
    Nervenarzt; 1996 Mar; 67(3):256-61. PubMed ID: 8901286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlled cross-over comparison of isofloxythepin and perphenazine in the treatment of schizophrenic psychoses.
    Svestka J; Náhunek K; Cesková E; Rysánek R; Balsíková J
    Act Nerv Super (Praha); 1989 Apr; 31(1):32-4. PubMed ID: 2571218
    [No Abstract]   [Full Text] [Related]  

  • 35. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial.
    Petit M; Raniwalla J; Tweed J; Leutenegger E; Dollfus S; Kelly F
    Psychopharmacol Bull; 1996; 32(1):81-7. PubMed ID: 8927680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zotepine in the treatment of negative symptoms in chronic schizophrenia.
    Fleischhacker WW; Barnas C; Stuppäck C; Unterweger B; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):58-60. PubMed ID: 2883684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with the neuroleptic zotepine--first results.
    Haug HJ
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):35-7. PubMed ID: 2883679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zotepine-induced convulsive seizures in a chronic case of treatment resistant paranoid schizophrenia.
    Khairkar P; Gupta N; Varma SK
    Indian J Pharmacol; 2013; 45(1):95-7. PubMed ID: 23543675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effectiveness of zotepine in therapy-refractory psychoses. An open, multicenter study in eight psychiatric clinics].
    Harada T; Otsuki S; Fujiwara Y
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():41-4. PubMed ID: 1683339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isofloxythepine in an open study.
    Papezová H; David I; Alda M; Soucek R
    Act Nerv Super (Praha); 1989 Jun; 31(2):121-2. PubMed ID: 2572133
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.